NCT05928936
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Emory University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Chronic Kidney Disease
- Drug/Device/Intervention
- Sodium Bicarbonate
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Emory University
- Location
- Atlanta,Decatur, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Nov 11, 2022
- End date
- Jun 01, 2028
- Enrollment
- 156 participants
Primary outcome
Change in Exercise Capacity
Summary
The goals of this project are to investigate the mechanisms and potential therapies related
 to exercise capacity in persons with chronic kidney disease (CKD).
ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05928936
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05928936 through Pure Global AI's free database. This Phase 2 trial is sponsored by Emory University and is currently Recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 156 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.